Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Exact Sciences (EXAS) to $72 from $69 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results which showed early signs of improved commercial execution.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences: Strong Q1 Performance and Promising Prospects Justify Buy Rating
- Exact Sciences price target raised to $75 from $55 at Barclays
- Exact Sciences Reports Strong Q1 2025 Results
- Closing Bell Movers: Apple and Amazon slip after earnings
- Exact Sciences reports Q1 EPS (54c) vs (60c) last year